Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis

mAbs

Volumn 4, Issue 5, 2012, Pages 600-613

  Kanakaraj, Palanisamy ^a   Puffer, Bridget A ^a   Yao, Xiao Tao ^a   Kankanala, Spandana ^a   Boyd, Ernest ^a   Shah, Rutul R ^a   Wang, Geping ^a   Patel, Dimki ^a   Krishnamurthy, Rajesh ^a   Kaithamana, Shashi ^a   Smith, Rodger G ^a   LaFleur, David W ^a   Barbas III, Carlos F ^b   Hilbert, David M ^a   Kiener, Peter A ^a   Roschke, Viktor V ^a  

^a Zyngenia Inc   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Adalimumab; Ang2; Arthritis; Bispecific antibody; Inflammation; TNF; Zybody

Indexed keywords

ADALIMUMAB; ANGIOPOIETIN 2; BISPECIFIC ANTIBODY;

ANIMAL MODEL; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DOSE RESPONSE; GEL PERMEATION CHROMATOGRAPHY; HEAVY CHAIN; IN VIVO STUDY; JOINT; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; CELL LINE; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MICE; MICE, TRANSGENIC; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VESICULAR TRANSPORT PROTEINS;

EID: 84866552180     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.21227     Document Type: Article

References (81)

1. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761.
2. Karampetsou MP, Liossis SN, Sfikakis PP. TNF-αantagonists beyond approved indications: stories of success and prospects for the future. QJM 2010; 103:917-28; PMID:20802008; http://dx.doi.org/10.1093/qjmed/hcq152.
3. Rigby WF. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passiveaggressive behavior? Nat Clin Pract Rheumatol 2007; 3:227-33; PMID:17396108; http://dx.doi.org/10.1038/ncprheum0438.
4. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117:244-79; PMID:18155297; http://dx.doi.org/10.1016/j.pharmthera.2007.10. 001.
5. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004; 15:280-94; PMID:15370396; http://dx.doi.org/10.1080/09546630410017275.
6. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009; 5:531- 41; PMID:19798027; http://dx.doi.org/10. 1038/nrrheum.2009.182.
7. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004; 50:277-90; PMID:14730626; http://dx.doi.org/10.1002/art.11487.
8. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al.; 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50:1412-9; PMID:15146410; http://dx.doi.org/10.1002/art.20221.
9. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007; 66:228-34; PMID:16935912; http://dx.doi.org/10.1136/ard. 2006.055111.
10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335- 42; PMID:15175435; http://dx.doi.org/10.1056/NEJMoa032691.
11. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329-38; PMID:17046465; http://dx.doi.org/10. 1016/S0140-6736(06)69446-4.
12. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516- 24; PMID:16757724; http://dx.doi.org/10.1001/jama.295.21.2516.
13. Dixon JA, Oliver SC, Olson JL, Mandava N. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2009; 18:1573-80; PMID:19694600; http://dx.doi.org/10.1517/13543780903201684.
14. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90; PMID:18650514; http://dx.doi.org/10.1056/ NEJMoa0708857.
15. Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, et al. A human monoclonal anti- ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010; 9:145-56; PMID:20053776; http://dx.doi.org/10.1158/1535- 7163.MCT-09-0554.
16. Hashizume H, Falcón BL, Kuroda T, Baluk P, Coxon A, Yu D, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70:2213-23; PMID:20197469; http://dx.doi.org/10.1158/0008-5472.CAN-09-1977.
17. Huang H, Lai JY, Do J, Liu D, Li L, Del Rosario J, et al. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 2011; 17:1001-11; PMID:21233403; http://dx.doi.org/10.1158/1078-0432.CCR-10-2317.
18. Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004; 6:507-16; PMID:15542434; http://dx.doi.org/10.1016/j.ccr.2004.09.030.
19. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009; 27:3557-65; PMID:19546406; http://dx.doi.org/10.1200/JCO.2008.19. 6683.
20. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, et al. Randomized, Double- Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer. J Clin Oncol 2011; PMID:22184370.
21. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999; 13:1055-66; PMID:10323857; http://dx.doi.org/10.1101/gad.13.9.1055.
22. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277:55-60; PMID:9204896; http://dx.doi.org/10.1126/ science.277.5322.55.
23. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87:1161-9; PMID:8980223; http://dx.doi.org/10. 1016/S0092-8674(00)81812-7.
24. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87:1171-80; PMID:8980224; http://dx.doi.org/10.1016/S0092-8674(00)81813-9.
25. Huang J, Bae JO, Tsai JP, Kadenhe-Chiweshe A, Papa J, Lee A, et al. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int J Oncol 2009; 34:79-87; PMID:19082480.
26. Davis S, Papadopoulos N, Aldrich TH, Maisonpierre PC, Huang T, Kovac L, et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol 2003; 10:38-44; PMID:12469114; http://dx.doi.org/10.1038/nsb880.
27. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, Koh GY. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Oncogene 2000; 19:4549-52; PMID:11002428; http://dx.doi.org/10.1038/sj.onc.1203800.
28. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, Bendeck MP, et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 2001; 49:659-70; PMID:11166279; http://dx.doi.org/10.1016/S0008-6363(00)00231-5.
29. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, et al. Tie2 receptor ligands, angiopoietin- 1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998; 83:233- 40; PMID:9710115; http://dx.doi.org/10.1161/01.RES.83.3.233.
30. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006; 27:552-8; PMID:17045842; http://dx.doi.org/ 10.1016/j.it.2006.10.004.
31. Koutroubakis IE, Tsiolakidou G, Karmiris K, Kouroumalis EA. Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12:515-23; PMID:16775497; http://dx.doi.org/10.1097/00054725-200606000-00012.
32. Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 2007; 10:149-66; PMID:17457680; http://dx.doi.org/10.1007/s10456-007-9074-0.
33. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997; 11:457-65; PMID:9194526.
34. Kim H, Koh GY. Ang2, the instigator of inflammation. Blood 2011; 118:4767-8; PMID:22053174; http://dx.doi.org/10.1182/blood-2011-09-377333.
35. Sone H, Kawakami Y, Sakauchi M, Nakamura Y, Takahashi A, Shimano H, et al. Neutralization of vascular endothelial growth factor prevents collageninduced arthritis and ameliorates established disease in mice. Biochem Biophys Res Commun 2001; 281:562- 8; PMID:11181084; http://dx.doi.org/10.1006/ bbrc.2001.4395.
36. Tolstanova G, Khomenko T, Deng X, Chen L, Tarnawski A, Ahluwalia A, et al. Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF. J Pharmacol Exp Ther 2009; 328:749-57; PMID:19060224; http://dx.doi.org/10.1124/jpet.108.145128.
37. Jung K, Lee D, Lim HS, Lee SI, Kim YJ, Lee GM, et al. Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. J Biol Chem 2011; 286:14410- 8; PMID:21345791; http://dx.doi.org/10.1074/jbc.M111.228130.
38. Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 2000; 87:603- 7; PMID:11009566; http://dx.doi.org/10.1161/01.RES.87.7.603.
39. McCarter SD, Mei SH, Lai PF, Zhang QW, Parker CH, Suen RS, et al. Cell-based angiopoietin-1 gene therapy for acute lung injury. Am J Respir Crit Care Med 2007; 175:1014-26; PMID:17322110; http://dx.doi.org/10.1164/rccm. 200609-1370OC.
40. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 2007; 4:e269; PMID:17803352; http://dx.doi.org/10.1371/journal.pmed.0040269.
41. Pizurki L, Zhou Z, Glynos K, Roussos C, Papapetropoulos A. Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br J Pharmacol 2003; 139:329- 36; PMID:12770938; http://dx.doi.org/10.1038/sj.bjp. 0705259.
42. 2- integrin-dependent manner. Blood 2011; 118:5050-9; PMID:21868579; http://dx.doi.org/10.1182/blood-2011-03-343293.
43. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004; 103:4150-6; PMID:14976056; http://dx.doi.org/10.1182/blood-2003-10-3685.
44. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12:235-9; PMID:16462802; http://dx.doi.org/10.1038/nm1351.
45. Roviezzo F, Tsigkos S, Kotanidou A, Bucci M, Brancaleone V, Cirino G, et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 2005; 314:738-44; PMID:15870388; http://dx.doi.org/10.1124/ jpet.105.086553.
46. Ganta VC, Cromer W, Mills GL, Traylor J, Jennings M, Daley S, et al. Angiopoietin-2 in experimental colitis. Inflamm Bowel Dis 2010; 16:1029-39; PMID:19902545.
47. Kümpers P, David S, Haubitz M, Hellpap J, Horn R, Bröcker V, et al. The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus. Ann Rheum Dis 2009; 68:1638- 43; PMID:18930996; http://dx.doi.org/10.1136/ard.2008.094664.
48. Giuliano JS Jr., Wheeler DS. Excess circulating angiopoietin-2 levels in sepsis: harbinger of death in the intensive care unit? Crit Care 2009; 13:114; PMID:19226440; http://dx.doi.org/10.1186/cc7685.
49. Kümpers P, van Meurs M, David S, Molema G, Bijzet J, Lukasz A, et al. Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis. Crit Care 2009; 13:R64; PMID:19416526; http://dx.doi.org/10.1186/ cc7866.
50. Michalska-Jakubus M, Kowal-Bielecka O, Chodorowska G, Bielecki M, Krasowska D. Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatology (Oxford) 2011; 50:746-55; PMID:21149250; http://dx.doi.org/10.1093/rheumatology/keq392.
51. Cho YJ, Ma JE, Yun EY, Kim YE, Kim HC, Lee JD, et al. Serum angiopoietin-2 levels are elevated during acute exacerbations of COPD. Respirology 2011; 16:284-90; PMID:21143700; http://dx.doi.org/10.1111/j.1440- 1843.2010.01915.x.
52. Kuroda K, Sapadin A, Shoji T, Fleischmajer R, Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 2001; 116:713-20; PMID:11348459; http://dx.doi.org/10.1046/j.1523- 1747.2001.01316.x.
53. Fearon U, Griosios K, Fraser A, Reece R, Emery P, Jones PF, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003; 30:260-8; PMID:12563678.
54. Westra J, de Groot L, Plaxton SL, BrouwerE, Posthumus MD, Kallenberg CG, et al. Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease. Rheumatology (Oxford) 2011; 50:665-73; PMID:21131273; http://dx.doi.org/10.1093/rheumatology/keq378.
55. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96:1788-95; PMID:17519900; http://dx.doi.org/10. 1038/sj.bjc.6603813.
56. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6:465-77; PMID:19581909; http://dx.doi.org/10.1038/nrclinonc.2009.94.
57. Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23:549-57; PMID:20457695; http://dx.doi.org/10.1093/protein/gzq028.
58. Marvin JS, Zhu Z. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 2005; 26:649-58; PMID:15916729; http://dx.doi.org/10.1111/j.1745-7254.2005.00119.x.
59. Makó V, Czúcz J, Weiszhár Z, Herczenik E, Matkó J, Prohászka Z, et al. Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1β, TNF-α, and LPS. Cytometry A 2010; 77:962- 70; PMID:21290470; http://dx.doi.org/10.1002/ cyto.a.20952.
60. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131:308-16; PMID:19188093; http://dx.doi.org/10.1016/j.clim.2009.01.002.
61. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008; 58:1248- 57; PMID:18438840; http://dx.doi.org/10.1002/art.23447.
62. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other antitumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13:1323-32; PMID:17636564; http://dx.doi.org/10.1002/ibd.20225.
63. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7:251-9; PMID:7640345; http://dx.doi.org/10.1006/cyto.1995.0029.
64. Koch AE. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003; 62(Suppl 2):ii60-7; PMID:14532152; http://dx.doi.org/10.1136/ard.62.suppl- 2.ii60.
65. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10:4025-31; PMID:1721867.
66. Douni E, Sfikakis PP, Haralambous S, Fernandes P, Kollias G. Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res Ther 2004; 6:R65-72; PMID:14979939; http://dx.doi.org/10.1186/ar1028.
67. Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011; 3:273- 88; PMID:21393993; http://dx.doi.org/10.4161/mabs.3.3.15188.
68. Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, et al. Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A 2010; 107:22611-6; PMID:21149738; http://dx.doi.org/10.1073/pnas.1016478108.
69. Demarest SJ, Hariharan K, Dong J. Emerging antibody combinations in oncology. MAbs 2011; 3:338- 51; PMID:21697653; http://dx.doi.org/10.4161/mabs.3. 4.16615.
70. Thakur A, Lum LG. Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther 2010; 12:340-9; PMID:20521223.
71. Fischer N, Léger O. Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 2007; 74:3-14; PMID:17496428; http://dx.doi.org/10.1159/000101046.
72. Hagemeyer CE, von Zur Muhlen C, von Elverfeldt D, Peter K. Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb Haemost 2009; 101:1012-9; PMID:19492141.
73. Song MY, Park SK, Kim CS, Yoo TH, Kim B, Kim MS, et al. Characterization of a novel anti-human TNF-alpha murine monoclonal antibody with high binding affinity and neutralizing activity. Exp Mol Med 2008; 40:35-42; PMID:18305396; http://dx.doi.org/10.3858/emm.2008.40.1.35.
74. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010; 49:1215-28; PMID:20194223; http://dx.doi.org/10. 1093/rheumatology/keq031.
75. Chen JX, Chen Y, DeBusk L, Lin W, Lin PC. Dual functional roles of Tie-2/angiopoietin in TNFalpha- mediated angiogenesis. Am J Physiol Heart Circ Physiol 2004; 287:H187-95; PMID:15210451; http://dx.doi.org/10.1152/ajpheart. 01058.2003.
76. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997; 17:4015-23; PMID:9199336.
77. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987; 329:630-2; PMID:2443857; http://dx.doi.org/10.1038/329630a0.
78. Kanakaraj P, Ngo K, Wu Y, Angulo A, Ghazal P, Harris CA, et al. Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. J Exp Med 1999; 189:1129-38; PMID:10190904; http://dx.doi.org/10.1084/jem.189.7.1129.
79. Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010; 16:3044-56; PMID:20501621; http://dx.doi.org/10. 1158/1078-0432.CCR-09-3368.
80. Robson EJ, Ghatage P. AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer. Expert Opin Investig Drugs 2011; 20:297-304; PMID:21210755; http://dx.doi.org/10.1517/13543784.2011.549125.
81. Shealy DJ, Wooley PH, Emmell E, Volk A, Rosenberg A, Treacy G, et al. Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res 2002; 4:R7; PMID:12223110; http://dx.doi.org/10. 1186/ar430.